HaploX Biotechnology

Focus: HaploX Biotechnology is a China-based biotech company specializing in genetic testing solutions with a focus on rare diseases and oncology indications. The company operates from Shenzhen and maintains an early-stage pipeline primarily targeting hepatocellular carcinoma and colorectal cancer.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About HaploX Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow HaploX Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MRD detection

Rectal Adenocarcinoma

N/A

Clinical Trials (1)

NCT05969938Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

N/A

Help build intelligence for HaploX Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build genetic testing capabilities in a high-growth Chinese biotech market with expanding rare disease focus
Early pipeline stage allows hands-on involvement in drug development from Phase 1 through Phase 2 programs
Geographic position in Shenzhen provides access to Asian clinical networks and patient populations for oncology trials

Watch Out For

Currently zero active job openings signals minimal hiring or potential organizational constraints
Limited pipeline maturity with only 1 Phase 2 program and 5 total trials suggests early-stage execution risk
Lack of public financials, funding data, and employee count raises transparency concerns for career stability assessment

Generated by Claude from HaploX Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Primary Hepatobiliary Cancer Cohort of Central China

Hepatocellular Carcinoma

N/A

Clinical Trials (1)

NCT05520801Primary Hepatobiliary Cancer Cohort of Central China

N/A

HAIC

Hepatocellular Carcinoma Non-resectable

N/A

Clinical Trials (1)

NCT05713994Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

N/A